Rezq Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $4M

Overview

Rezq Bio is a private, preclinical-stage biotech founded in 2021, pioneering a localized immunomodulation platform using dendritic cell therapies. Its lead program, RZQ-MC1 for early-onset Type 1 Diabetes, has completed a Phase 1A safety trial and is preparing for Phase 1B/2A, supported by a pipeline targeting colitis and transplant support. The company is targeting a large, underserved market in autoimmune diseases, beginning with T1D, which lacks disease-modifying treatments and affects millions globally. Its approach differentiates by aiming to restore immune tolerance locally without systemic immunosuppression.

Autoimmune DiseasesInflammatory DiseasesType 1 Diabetes

Technology Platform

A dendritic cell (DC) modulation platform designed to treat regional inflammation locally. It converts DCs from an inflammatory (mature) to a tolerant (immature) state, either ex vivo for autologous cell therapy or in situ via microsphere payloads, to restore immune tolerance without systemic immunosuppression.

Funding History

1

Total raised:$4M

Seed$4MUndisclosedJan 15, 2022

Opportunities

The primary opportunity is addressing the massive unmet need in Type 1 Diabetes, a chronic autoimmune disease with no disease-modifying therapies, affecting millions globally with a growing adult-onset population.

Success in T1D validates a platform that can be expanded to other localized inflammatory conditions (e.g., colitis) and into the transplant support market to reduce systemic immunosuppression, representing multiple multi-billion dollar addressable markets.

Risk Factors

Key risks include clinical failure to demonstrate efficacy in arresting T1D progression in upcoming trials, the significant financial burden of developing autologous cell therapies requiring ongoing capital raises, and regulatory challenges for a novel modality.

Competition from other disease-modifying approaches and platform risk if the lead program fails are also material threats.

Competitive Landscape

Rezq Bio competes in the T1D space against other companies developing disease-modifying therapies, including beta-cell replacement strategies (stem cell-derived islets, encapsulated cells), antigen-specific immunotherapies, and other immunomodulators. Its key differentiation is the localized, dendritic cell-centric approach aiming to restore immune tolerance without broad systemic immunosuppression, a side effect that plagues many other immunomodulatory and transplant approaches.

More companies in Cell & Gene Therapy →More companies in United States →